Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial

被引：0

作者：

Masip, J. Remon ^{[1
]}

Besse, B. ^{[1
]}

Aix, S. Ponce ^{[2
]}

Perez, A. Callejo ^{[3
]}

Al-Rabi, K. ^{[4
]}

Caro, R. Bernabe ^{[5
]}

Greillier, L. ^{[6
]}

Tarruella, M. Majem ^{[7
]}

Aransay, N. Reguart ^{[8
]}

Monnet, I. ^{[9
]}

Cousin, S. ^{[10
]}

Lopez, P. Garrido ^{[11
]}

Robinet, G. ^{[12
]}

Campelo, R. Garciaprime ^{[13
]}

Flandin, A-C. Madroszyk ^{[14
]}

Mazieres, J. ^{[15
]}

Curcio, H. ^{[16
]}

Pretzenbacher, Y. ^{[17
]}

Dingemans, A-M. C. ^{[18
]}

Dziadziuszko, R. ^{[19
]}

机构：

[1] Inst Gustave Roussy, Oncol Dept, Villejuif, France

[2] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[3] Vall dHebron Univ Hosp, Oncol Dept, Barcelona, Spain

[4] KHCC King Hussein Canc Ctr, Med Oncol & Hematol Dept, Amman, Jordan

[5] Hosp Univ Virgen Rocio, Seville, Spain

[6] Hop St Marguerite Assistance Publ Hop Marseille, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France

[7] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[8] Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain

[9] Chi Creteil, Creteil, France

[10] Inst Bergonie, Early Phase Trials, Bordeaux, France

[11] Hosp Univ Ramon & Cajal, Med Oncol Dept, Madrid, Spain

[12] CHRU Brest Hop Morvan, Brest, France

[13] CHUAC Complexo Hosp Univ A Coruna, La Coruna, Spain

[14] IPC Inst Paoli Calmettes, Marseille, France

[15] Ctr Hosp Univ Toulouse, Thorac Oncol Dept, Hop Larrey, Toulouse, France

[16] Ctr Francois Baclesse, Oncol Dept, Caen, France

[17] EORTC AISBL IVZW European Org Res & Treatment Can, Stat, Brussels, Belgium

[18] Erasmus MC Univ, Pulmonol Dept, Med Ctr, Rotterdam, Netherlands

[19] Med Univ Gdansk, Oncol & Radiotherapy Dept, Gdansk, Poland

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S35 / S35

页数：1

共 50 条

[31] MERTK activation drives osimertinib resistance in EGFR-mutant non small cell lung cancer
Yan, Dan
Huelse, Justus M.
Kireev, Dmitri
Tan, Zikang
Chen, Luxiao
Goyal, Subir
Wang, Xiaodong
Frye, Stephen, V
Behera, Madhusmita
Schneider, Frank
Ramalingam, Suresh S.
Owonikoko, Taofeek
Earp, H. Shelton
DeRyckere, Deborah
Graham, Douglas K.
JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (15):
[32] Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
Lemmon, Christopher A.
Zabor, Emily C.
Pennell, Nathan A.
ONCOLOGIST, 2022, 27 (05): : 407 - 413
[33] Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
Cai, Xueting
Miao, Jing
Sun, Rongwei
Wang, Sainan
Molina-Vila, Miguel Angel
Chaib, Imane
Rosell, Rafael
Cao, Peng
PHARMACOLOGICAL RESEARCH, 2021, 170
[34] Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
Naito, Yoichi
Goto, Koichi
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1027 - 1040
[35] A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results
Blakely, C.
Urisman, A.
Kerr, D.
Wu, W.
Bacaltos, B.
Rotow, J.
Gubens, M.
Jones, K.
Bivona, T.
Joo, S.
Riess, J.
Aisner, D.
Doebele, R.
Patil, T.
Schenk, E.
Kratz, J.
Jablons, D.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1039 - S1040
[36] Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada
Ezeife, Doreen A.
Kirk, Veronica
Chew, Derek S.
Nixon, Nancy A.
Lee, Roy
Le, Lisa W.
Chan, Kelvin K. -W.
Leighl, Natasha B.
LUNG CANCER, 2018, 125 : 1 - 7
[37] An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer
Shi, Yue
Jiang, Yingying
Pan, Banzhou
Wang, Zihan
Li, Hang
Ma, Yuxin
Liu, Yilin
He, Kang
Wang, Zhitong
Lu, Jianwei
Shi, Meiqi
Shen, Bo
Zhou, Guoren
Yin, Rong
Rossi, Antonio
Ito, Kentaro
Santarpia, Mariacarmela
Um, Sang-Won
Wang, Xiaohua
Chen, Cheng
Feng, Jifeng
TRANSLATIONAL LUNG CANCER RESEARCH, 2022, : 817 - 831
[38] Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.
Kim, Chul
Roper, Nitin
Hoang, Chuong D.
Szabo, Eva
Connolly, Maureen
Padiernos, Emerson
Kesarwala, Aparna Hemant
Cultraro, Constance
Waris, Maryam
Gao, Shaojian
Steinberg, Seth M.
Wong, David T.
Khan, Laved
Rajan, Arun
Guha, Udayan
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[39] Multicentered Real-World Evidence of Osimertinib Treatment in EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) In Thailand
Thamrongjirapat, T.
Sitthideatphaiboon, P.
Oranratnachai, S.
Khiewngam, K.
Maneenil, K.
Prasongsook, N.
Korphaisarn, K.
Wangsubtawee, S.
Rattanaphom, A.
Reungwetwattana, T.
Sriuranpong, V.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S624 - S625
[40] Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
Ahn, M. -J.
Yang, J.
Yu, H.
Saka, H.
Ramalingam, S.
Goto, K.
Kim, S. -W.
Yang, L.
Walding, A.
Oxnard, G. R.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S115 - S115

← 1 2 3 4 5 →